Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...

The symptoms of hyperkalemia begin with muscle weakness. As serum potassium levels rise, symptoms progress to more significant muscle twitching, weakness, nausea, and cramping. [69] Cardiac ...

Research suggests that vitamin D plays a role in regulating the renin-angiotensin-aldosterone system (RAAS), a critical pathway involved in blood pressure regulation. Vitamin D has been shown to ...

Infusion of angiotensin has been consistently shown to induce an increased secretion of aldosterone by the adrenal cortex in normal human subjects. Because renal damage is so prominent in malignant ...

GOVERNOR MAURA HEALEY RECENTLY SIGNED IT INTO LAW AS THE PHYSICIAN PATHWAY ACT. A BUSY PRIMARY CARE DOCTOR TAKES CARE OF 1500 TO UP TO 2000 PATIENTS, SO JUST EVEN ONE PERSON GO INTO A COMMUNITY ...

In a world filled with uncertainty, hope provides a pathway to resilience and growth. By focusing on future possibilities, setting meaningful goals, and believing in the capacity to achieve them ...

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) and a drug targeting the mineralocorticoid receptor (MR) pathway that has demonstrated cardiovascular ... By ...

then an ACE inhibitor or angiotensin receptor blocker should be considered. If the renin level is low while on a diuretic, then an aldosterone antagonist could be considered.

2001). We further assessed the correlation between renin-angiotensin system and NF-κB activity, and identified a positive correlation between the levels of Ang II and phosphorylated NF-κB-p65, and a ...